U.S. stocks closed lower as investors attempted to find clarity on the timing of a rate hike amid concerns of the dollar's impact on earnings.» Read More
More companies announced layoffs as the employment picture continued to dim.
Dr. Steven Nissen, the cardiology chief at the Cleveland Clinic, reportedly remains on the shortlist to possibly become the next FDA Commissioner. Some analysts believe if Dr. Nissen gets the nod there could be a negative knee-jerk reaction in the big pharma sector stocks.
Even on Inauguration Day, companies continued to announce layoffs, reinforcing the challenges facing Barack Obama.
Stocks ended a dismal week on an up note as investors took some defensive positions in stocks like McDonald's amid nagging worries about the health of banks.
Corporate layoffs have soared since New Year's. On Friday alone, GE, Pfizer, AMD, Wellpoint and Hertz announced big cuts.
Even though it's one of the leading causes of cancer death in the U.S., pancreatic normally doesn't get much attention.
And that's not all. Energy plays, housing stocks, retailers – they're all victims of an under-the-radar trend in the markets.
Speculation is swirling that Elan could be on the brink of merger after the firm hired Citigroup to conduct a strategic review. Find out what the Fast Money traders are hearing.
Stocks ended mixed Tuesday as tech and oil stocks were buoyed by bargain hunting, but the undercurrent of earnings worry took down the Dow.
During his lunchtime keynote speech here at the JPMorgan Healthcare Conference JPM Chairman and CEO Jamie Dimon was asked to give his worst-case scenario for the economy. He said that'd be a 1982-type recession lasting about two years and with unemployment "North of 10 percent." Dimon said it would be "Irrational to not be prepared for that."
Stocks wobbled Tuesday, paring some gains, though the tech-heavy Nasdaq remained higher.
Not surprisingly it was standing room only in the grand ballroom of the Westin St. Francis Hotel in San Francisco for the Roche presentation this morning at the JPMorgan Healthcare Conference.
Wall Street was looking at a slightly lower open Monday as traders took a leery view of the kickoff to earnings season.
Will M&A activity boost biotech stocks in 2009?
Stocks snapped a three-day winning streak Monday as traders cashed in some of their chips from last week's rally following some dismal reports on the telecom and financial sectors.
Stocks turned mixed Monday, the second day of trading in the new year, as a construction report came in much better than expected, as did U.S. auto sales. Stocks started off the day sharply lower as investors cashed in some of their chips after last week's rally that pushed the Dow up more than 6 percent and past the key 9,000 mark.
Biotechnology stocks are getting a lot of chatter already in this very young year.
The "Financial Times" apparently got a one-on-one interview with Pfizer Chairman and CEO Jeff Kindler and is playing up what he said with the headline, "Pfizer eyes merger deal with large rival."
Stocks declined Monday, the second day of trading in the new year, after a rally last week that pushed the Dow up more than 6 percent and past the key 9,000 mark. A report that showed construction spending fell by half of what was expected helped shave some of the loss.
We begin the "real" New Year with stocks at a 6-week high, and the S&P 500 24 percent above its November 20 low. Now let's see if we can change leadership: health care and consumer stocks have generally outperformed in the past few weeks, though recently industrial stocks have improved. A shift toward less defensive names would be a welcome development.